BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQ: BCRX · Real-Time Price · USD
7.49
+0.19 (2.60%)
At close: Nov 21, 2024, 4:00 PM
7.45
-0.04 (-0.53%)
After-hours: Nov 21, 2024, 5:59 PM EST
BioCryst Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
Cash & Equivalents | 96.84 | 110.64 | 304.77 | 504.39 | 272.13 | 114.17 | Upgrade
|
Short-Term Investments | 233.17 | 278.34 | 119.54 | 3.21 | 28.24 | 22.05 | Upgrade
|
Cash & Short-Term Investments | 330.01 | 388.99 | 424.31 | 507.6 | 300.37 | 136.23 | Upgrade
|
Cash Growth | -17.00% | -8.32% | -16.41% | 68.99% | 120.49% | 30.40% | Upgrade
|
Receivables | 72.46 | 56.95 | 50.6 | 29.41 | 8.65 | 22.15 | Upgrade
|
Inventory | 7.56 | 28.68 | 27.53 | 15.79 | 7.04 | - | Upgrade
|
Prepaid Expenses | 16.28 | 19.54 | 12.59 | 9.99 | 5.53 | 4.42 | Upgrade
|
Restricted Cash | 0.81 | 1.8 | 1.47 | 3.35 | 2.22 | 1.55 | Upgrade
|
Total Current Assets | 427.13 | 495.97 | 516.5 | 566.14 | 323.8 | 164.35 | Upgrade
|
Property, Plant & Equipment | 19.63 | 20.91 | 15.42 | 15.19 | 10.92 | 10.94 | Upgrade
|
Long-Term Investments | 19.43 | - | 18.08 | 6.83 | - | - | Upgrade
|
Other Long-Term Assets | 25.07 | 0.08 | - | - | - | - | Upgrade
|
Total Assets | 491.25 | 516.96 | 550 | 588.15 | 334.72 | 175.28 | Upgrade
|
Accounts Payable | 13.48 | 20.89 | 14.36 | 27.81 | 18.71 | 13.99 | Upgrade
|
Accrued Expenses | 104.2 | 102.88 | 87.57 | 72.67 | 55.61 | 36.27 | Upgrade
|
Current Portion of Long-Term Debt | 33 | 23.57 | - | - | 30 | 38.58 | Upgrade
|
Current Portion of Leases | 2.89 | 2.65 | 2.37 | 1.82 | 1.18 | 1.38 | Upgrade
|
Current Unearned Revenue | - | - | 1.22 | 1.42 | 0.15 | 2.12 | Upgrade
|
Total Current Liabilities | 153.57 | 149.99 | 105.51 | 103.72 | 105.65 | 92.34 | Upgrade
|
Long-Term Debt | 796.11 | 811.27 | 733.28 | 585.46 | 244.45 | 41.29 | Upgrade
|
Long-Term Leases | 10.14 | 11.24 | 5.8 | 5.96 | 3.87 | 3.41 | Upgrade
|
Total Liabilities | 959.82 | 972.49 | 844.6 | 695.14 | 353.98 | 137.03 | Upgrade
|
Common Stock | 2.07 | 2.06 | 1.88 | 1.84 | 1.77 | 1.54 | Upgrade
|
Additional Paid-In Capital | 1,270 | 1,222 | 1,158 | 1,098 | 1,002 | 877.3 | Upgrade
|
Retained Earnings | -1,743 | -1,681 | -1,455 | -1,208 | -1,023 | -840.63 | Upgrade
|
Comprehensive Income & Other | 2.29 | 1.34 | 0.03 | 0.18 | 0 | 0.04 | Upgrade
|
Shareholders' Equity | -468.56 | -455.53 | -294.6 | -106.99 | -19.26 | 38.25 | Upgrade
|
Total Liabilities & Equity | 491.25 | 516.96 | 550 | 588.15 | 334.72 | 175.28 | Upgrade
|
Total Debt | 842.14 | 848.71 | 741.45 | 593.24 | 279.5 | 84.65 | Upgrade
|
Net Cash (Debt) | -512.13 | -459.73 | -317.14 | -85.64 | 20.86 | 51.57 | Upgrade
|
Net Cash Growth | - | - | - | - | -59.54% | 20.94% | Upgrade
|
Net Cash Per Share | -2.50 | -2.39 | -1.71 | -0.48 | 0.12 | 0.45 | Upgrade
|
Filing Date Shares Outstanding | 207.13 | 206.15 | 188.45 | 184.66 | 177.18 | 154.19 | Upgrade
|
Total Common Shares Outstanding | 207.12 | 205.77 | 187.91 | 184.35 | 176.88 | 154.08 | Upgrade
|
Working Capital | 273.56 | 345.98 | 410.99 | 462.42 | 218.15 | 72.01 | Upgrade
|
Book Value Per Share | -2.26 | -2.21 | -1.57 | -0.58 | -0.11 | 0.25 | Upgrade
|
Tangible Book Value | -468.56 | -455.53 | -294.6 | -106.99 | -19.26 | 38.25 | Upgrade
|
Tangible Book Value Per Share | -2.26 | -2.21 | -1.57 | -0.58 | -0.11 | 0.25 | Upgrade
|
Machinery | - | 7.66 | 6.53 | 5.84 | 4.71 | 4.25 | Upgrade
|
Leasehold Improvements | - | 10.21 | 10.14 | 9.83 | 8.58 | 8.53 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.